Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Follow-Up Questions
Agenus Inc 'in CEO'su kimdir?
Dr. Garo Armen 1994 'den beri şirketle birlikte olan Agenus Inc 'in Chairman of the Board 'ıdır.
AGEN hissesinin fiyat performansı nasıl?
AGEN 'in mevcut fiyatı $4 'dir, son işlem günde 3.11% increased etti.
Agenus Inc için ana iş temaları veya sektörler nelerdir?
Agenus Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Agenus Inc 'in piyasa değerlemesi nedir?
Agenus Inc 'in mevcut piyasa değerlemesi $127.4M 'dir
Agenus Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 5 analist Agenus Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 5 al, 2 tut, 0 sat ve 2 güçlü sat içermektedir
